Franklin Genomic Valuation
| HELX Etf | USD 27.13 0.37 1.35% |
At this time, the entity appears to be fairly valued. Franklin Genomic Adv shows a prevailing Real Value of $27.12 per share. The current price of the entity is $27.13. Our model computes the value of Franklin Genomic Adv from reviewing the entity fundamentals such as Equity Positions Weight of 98.96 %, net asset of 10.39 M, and One Year Return of (16.30) % as well as analyzing its technical indicators and probability of bankruptcy.
Fairly Valued
Today
Please note that Franklin Genomic's price fluctuation is very steady at this time. Calculation of the real value of Franklin Genomic Adv is based on 3 months time horizon. Increasing Franklin Genomic's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Franklin Genomic is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Franklin Etf. However, Franklin Genomic's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 27.13 | Real 27.12 | Hype 27.16 | Naive 27.18 |
The intrinsic value of Franklin Genomic's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Franklin Genomic's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Franklin Genomic Advancements helps investors to forecast how Franklin etf's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Franklin Genomic more accurately as focusing exclusively on Franklin Genomic's fundamentals will not take into account other important factors: About Franklin Genomic Valuation
Our relative valuation model uses a comparative analysis of Franklin Genomic. We calculate exposure to Franklin Genomic's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Franklin Genomic's related companies.Under normal market conditions, the fund invests at least 80 percent of its net assets in equity securities of companies that are relevant to its investment theme of genomic advancements. Franklin Genomic is traded on BATS Exchange in the United States.
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Franklin Genomic Advancements. Also, note that the market value of any etf could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.
The market value of Franklin Genomic Adv is measured differently than its book value, which is the value of Franklin that is recorded on the company's balance sheet. Investors also form their own opinion of Franklin Genomic's value that differs from its market value or its book value, called intrinsic value, which is Franklin Genomic's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Franklin Genomic's market value can be influenced by many factors that don't directly affect Franklin Genomic's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Franklin Genomic's value and its price as these two are different measures arrived at by different means. Investors typically determine if Franklin Genomic is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Franklin Genomic's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.